Lotilaner Ophthalmic Solution 0.25%: First Approval

Lotilaner ophthalmic solution 0.25% (XDEMVY™), a gamma-aminobutyric acid-gated chloride channel (GABA-Cl) inhibitor selective for mites, is being developed by Tarsus Pharmaceuticals for the treatment of Demodex blepharitis and meibomian gland dysfunction in patients with Demodex lid infestation (Dem...

Descripción completa

Detalles Bibliográficos
Autor principal: Syed, Yahiya Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624734/
https://www.ncbi.nlm.nih.gov/pubmed/37843754
http://dx.doi.org/10.1007/s40265-023-01947-9
_version_ 1785130977161379840
author Syed, Yahiya Y.
author_facet Syed, Yahiya Y.
author_sort Syed, Yahiya Y.
collection PubMed
description Lotilaner ophthalmic solution 0.25% (XDEMVY™), a gamma-aminobutyric acid-gated chloride channel (GABA-Cl) inhibitor selective for mites, is being developed by Tarsus Pharmaceuticals for the treatment of Demodex blepharitis and meibomian gland dysfunction in patients with Demodex lid infestation (Demodex-induced meibomianitis). On 24 July 2023, lotilaner ophthalmic solution 0.25% received its first approval in the USA for the treatment of Demodex blepharitis. The agent is also currently in phase 3 development for Demodex blepharitis in China and phase 2 development for Demodex-induced meibomianitis in the USA. This article summarizes the milestones in the development of lotilaner ophthalmic solution 0.25% leading to this first approval for the treatment of Demodex blepharitis in the USA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-023-01947-9.
format Online
Article
Text
id pubmed-10624734
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106247342023-11-05 Lotilaner Ophthalmic Solution 0.25%: First Approval Syed, Yahiya Y. Drugs AdisInsight Report Lotilaner ophthalmic solution 0.25% (XDEMVY™), a gamma-aminobutyric acid-gated chloride channel (GABA-Cl) inhibitor selective for mites, is being developed by Tarsus Pharmaceuticals for the treatment of Demodex blepharitis and meibomian gland dysfunction in patients with Demodex lid infestation (Demodex-induced meibomianitis). On 24 July 2023, lotilaner ophthalmic solution 0.25% received its first approval in the USA for the treatment of Demodex blepharitis. The agent is also currently in phase 3 development for Demodex blepharitis in China and phase 2 development for Demodex-induced meibomianitis in the USA. This article summarizes the milestones in the development of lotilaner ophthalmic solution 0.25% leading to this first approval for the treatment of Demodex blepharitis in the USA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-023-01947-9. Springer International Publishing 2023-10-16 2023 /pmc/articles/PMC10624734/ /pubmed/37843754 http://dx.doi.org/10.1007/s40265-023-01947-9 Text en © Springer Nature 2023, corrected publication 2023 https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle AdisInsight Report
Syed, Yahiya Y.
Lotilaner Ophthalmic Solution 0.25%: First Approval
title Lotilaner Ophthalmic Solution 0.25%: First Approval
title_full Lotilaner Ophthalmic Solution 0.25%: First Approval
title_fullStr Lotilaner Ophthalmic Solution 0.25%: First Approval
title_full_unstemmed Lotilaner Ophthalmic Solution 0.25%: First Approval
title_short Lotilaner Ophthalmic Solution 0.25%: First Approval
title_sort lotilaner ophthalmic solution 0.25%: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624734/
https://www.ncbi.nlm.nih.gov/pubmed/37843754
http://dx.doi.org/10.1007/s40265-023-01947-9
work_keys_str_mv AT syedyahiyay lotilanerophthalmicsolution025firstapproval

Ejemplares similares